Trial Profile
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Sep 2021
Price :
$35
*
At a glance
- Drugs Uproleselan (Primary) ; Cytarabine; Etoposide; Idarubicin; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors GlycoMimetics
- 23 Sep 2021 Results published in the GlycoMimetics Media Release
- 20 Sep 2021 Results assessing the safety, tolerability, and anti-leukemic activity of uproleselan with MEC (mitoxantrone, etoposide, cytarabine) among patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) published in the Blood
- 06 Nov 2019 According to a GlycoMimetics media release, data will be presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition.